Establishing Physiologic Outcomes for Ventricular Unloading on VA ECMO

Status Recruiting

Clinical Trial Summary

Aim 1: Prospective, observational analysis of the association between echocardiographic measures of cardiac function and left ventricular unloading on VA ECMO. Aim 2: Prospective, observational analysis of the association between clinical laboratory biomarkers and left ventricular unloading on VA ECMO.

Clinical Trial Description

Mechanical circulatory support (MCS) is increasingly utilized as a means of hemodynamic support among cardiogenic shock (CS) patients refractory to optimal medical management. MCS modalities include using either an intra-aortic balloon pump (IABP), Impella®, or ECMO, each with unique benefit/harm profiles. Among the various MCS devices, extracorporeal membrane oxygenation (ECMO) is described as the highest level of support, capable of providing 5+ liters per minute of oxygenated blood flow but is the most invasive. Despite the benefit of maximal cardiopulmonary support, ECMO increases afterload in a failing heart. Left ventricular (LV) unloading or decompression (using simultaneous IABP or Impella®) has been suggested as potential improvement. Observational studies suggest a benefit with LV unloading during VA ECMO for CS, but the mechanisms underlying the association are poorly understood. Prior to trials, a mechanistic understanding of the effect of different LV unloading strategies on key physiologic abnormalities in CS is needed, as the physiologic effects of LV unloading during VA ECMO for CS remain insufficiently defined. The objective of this study is to define serial changes in common clinical variables routinely obtained during management of patients in CS. These clinical variables are readily accessible to clinicians, but are not typically collected in a sufficiently granular serial manner to characterize their utility as clinical biomarkers. By obtaining scheduled assessments, repeated in a prospective cohort over the clinical course of CS, the investigators will define the physiologic effects of different LV unloading strategies in cardiogenic shock. We will examine a) echocardiographic measures of ventricular distension, and b) blood biochemical measures of peripheral perfusion. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05658276
Study type	Observational
Source	University of Utah
Contact	Joseph E Tonna, MD
Phone	801-581-5311
Email	joseph.tonna@hsc.utah.edu
Status	Recruiting
Phase
Start date	December 15, 2023
Completion date	September 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03283995` - Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
Active, not recruiting	`NCT04325035` - The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock	Phase 2
Active, not recruiting	`NCT05100836` - SURPASS Impella 5.5 Study
Not yet recruiting	`NCT05106491` - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients	N/A
Completed	`NCT02301819` - ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock	N/A
Completed	`NCT01367743` - Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock	Phase 4
Recruiting	`NCT05728359` - Genomic Determinants of Outcome in Cardiogenic Shock
Recruiting	`NCT05699005` - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO	Phase 1
Not yet recruiting	`NCT06338345` - Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients	N/A
Completed	`NCT03436641` - Microcirculation in Cardiogenic Shock
Recruiting	`NCT03313687` - SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
Recruiting	`NCT05506449` - The RECOVER IV Trial	N/A
Completed	`NCT04144660` - "Treatment Use of ECMO In Pregnancy or Peripartum Patient."
Completed	`NCT04548739` - Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
Recruiting	`NCT04141410` - Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
Not yet recruiting	`NCT05879276` - Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.	Phase 3
Enrolling by invitation	`NCT05570864` - Score TO Predict SHOCK - STOP SHOCK
Completed	`NCT02591771` - Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock	Phase 2
Terminated	`NCT02279979` - Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial	N/A
Completed	`NCT01374867` - CardShock Study and Registry	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.